Nasoflu (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors inside nasal mucosal cells. This binding alters gene transcription, leading to reduced production of inflammatory cytokines and chemokines, which diminishes immune cell infiltration and vascular permeability, thereby decreasing nasal inflammation and associated symptoms.

The appropriate dose of Nasoflu is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product’s labeling for the correct number of sprays per nostril.

Safety data for fluticasone propionate in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing Nasoflu to pregnant or nursing mothers. Patients should discuss their individual situation with a qualified professional.

To request Nasoflu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nasoflu’s active ingredient, fluticasone propionate, is a high‑potency glucocorticoid with minimal systemic absorption when used as directed. Compared with older nasal steroids, it offers effective symptom control with a favorable safety profile, though individual response and tolerability can vary among patients.

Nasoflu should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and efficacy throughout its shelf life.

Nasoflu is administered as a nasal spray. The patient gently tilts the head forward, inserts the nozzle into one nostril, and sprays the prescribed number of actuations while breathing in gently. The process is then repeated in the other nostril if required.

Serious but rare risks include nasal septal perforation, elevated intra‑ocular pressure leading to glaucoma or cataract formation, and systemic adrenal suppression with prolonged high‑dose use. Patients should report persistent nosebleeds, visual changes, or signs of systemic steroid effects to their healthcare provider promptly.

Nasoflu should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections until the infection is resolved, and caution is advised for those with uncontrolled glaucoma or cataracts.